The text provides recommendations for the treatment of non-metastatic colon cancer, including mono-chemotherapy with fluoropyrimidine for patients over 70, adjuvant chemotherapy with fluoropyrimidines and oxaliplatin for stage III regardless of tumor status, and alternative treatments for patients unable to tolerate oxaliplatin. It also suggests genotyping the DPYD gene for abnormal phenotypes and encouraging moderate physical activity for patients.